Skip to Main Content

Paper Details

Response to olaparib in a <i>PALB2</i> germline mutated prostate cancer and genetic events associated with resistance.
Cold Spring Harb Mol Case Stud
28
2019
DNA repair gene, PALB2, PARP, Prostate cancers, RB1, RNA, advanced prostate cancer, neuroendocrine prostate cancer, olaparib, patient, patients, platinum, prostate cancer
Author NameAffiliation
Peter HorakNational Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ)
Peter HorakDKFZ-Heidelberg Center for Personalized Oncology (HIPO)
Peter Horak
Joachim WeischenfeldtUniversity of Copenhagen and Rigshospitalet
Joachim WeischenfeldtCharite-Universitatsmedizin Berlin
Joachim WeischenfeldtUniversity of Copenhagen and Rigshospitalet
Joachim WeischenfeldtCharite-Universitatsmedizin Berlin
Sebastian Uhrig
Sebastian Uhrig
Sebastian UhrigHeidelberg University
Lars Feuerbach
Lars Feuerbach
Daniel H??bschmann
Daniel H??bschmannGermany and Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH)
Daniel H??bschmannHeidelberg University Hospital
Daniel H??bschmann
Daniel H??bschmannHeidelberg University Hospital
Daniel H??bschmannGermany and Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH)
Simon KreutzfeldtNational Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ)
Simon Kreutzfeldt
Barbara Hutter
Barbara Hutter
Barbara Hutter
Barbara Hutter
Matthias Schlesner
Matthias Schlesner
Roland EilsUniversity of Heidelberg
Roland EilsCenter for Digital Health, Berlin Institute of Health and Charite Universitatsmedizin Berlin
Roland EilsUniversity of Heidelberg
Roland EilsCenter for Digital Health, Berlin Institute of Health and Charite Universitatsmedizin Berlin
Guido SauterInstitute of Pathology, University Medical Center Hamburg-Eppendorf
Albrecht Stenzinger
Albrecht StenzingerInstitute of Pathology, Heidelberg University Hospital
Benedikt Brors
Benedikt Brors
Benedikt Brors
Benedikt Brors
Stefan Fr??hlingNational Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ)
Stefan Fr??hlingDKFZ-Heidelberg Center for Personalized Oncology (HIPO)
Stefan Fr??hling
Thorsten SchlommCharite-Universitatsmedizin Berlin
  • 1 - 41

Datasets